Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasCellular TherapyIndolent LymphomasDiseaseCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbSubgroupICD10C82.-C82.7C82.9C83.3C91.1-MeSHLymphoma, Large B-Cell, DiffuseSequenceChemotherapyChemo-substanceCyclophosphamideFludarabineChemo-substanceCyclophosphamideFludarabineChemo-substanceCyclophosphamideFludarabineChemo-substanceCyclophosphamideFludarabineNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronNo. Substances3Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionRisksAnemia Hb below 8g/dlEmetogenicity (MASCC/ESMO)HypertensionLymphopeniaNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorLiu E DiseaseB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieOriginUniversity of Texas M.D. Anderson Cancer Center, HoustonProtocols in Revision 1 protocol foundProtocols under revision.Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471 V2.0)
